 Supernus Pharmaceuticals Inc. shares jumped more than 20 in after-hours trading Tuesday after the company revealed positive results from a study of its potential drug for attention deficit hyperactivity disorder, or ADHD. Supernus announced Tuesday afternoon that a phase 3 study of the drug, known as SPN-812, on adults achieved its targeted endpoint. 